Skip to main content

Advertisement

SpringerLink
Log in

Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

It is commonly accepted that apoptosis plays an important role in the death of normal and neoplastic cells. Related proteins and their receptors on cell surfaces regulate apoptosis. One of the best-characterized systems is the Fas-Fas ligand system. The aim of the study was to examine the concentrations of soluble Fas receptor (sFas) and the soluble ligand for the Fas receptor (sFasL) in serum of women with uterine tumors.

The study included 42 women with uterine tumors. As a normal control, sera were obtained from 20 healthy female volunteers. The concentrations of sFas and sFasL in serum were measured by enzyme-linked immunosorbent assay ELISA.

Significant increases of the mean value of sFas and sFasL were found in the serum of women with uterine tumor compared to the control group (p < 0.0001). The mean levels of these parameters increased in consecutive stages of the clinical extent of the uterine cancer (I-III). The lowest concentration was observed in women with stage I and the highest in women with stage III of clinical extent according to FIGO.

Apoptosis that appears to occur in the cancerous cells of malignant uterine tumors is associated with high levels of sFas and sFasL in serum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Furuya Y, Fuse H, Masai M. Serum soluble Fas level for detection and staging of prostate cancer. Anticancer Res 2001; 21: 3595–3598.

    PubMed  Google Scholar 

  2. Lim SC. Expression of Fas ligand and sFas ligand in human gastric adenocarcinomas. Oncol Rep 2002; 9: 103–107.

    PubMed  Google Scholar 

  3. Nagata S. Fas and Fas ligand: A death factor and its receptor. Adv Immunol 1994; 57: 129–144.

    PubMed  Google Scholar 

  4. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathway as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528–530.

    Google Scholar 

  5. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997; 18: 240–244.

    Article  PubMed  Google Scholar 

  6. Marsik C, Halama T, Cardona F, et al. Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans. Shock 2003; 20: 493–496.

    Article  PubMed  Google Scholar 

  7. Mizutani Y, Yoshida O, Bonavida B. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. J Urol 1998; 160; 571–576.

    Article  PubMed  Google Scholar 

  8. Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 1999; 5: 3529–3533.

    PubMed  Google Scholar 

  9. Nonomura N, Nishimura K, Ono Y, et al. Soluble Fas in serum from patients with renal cell carcinoma. Urology 2000; 55: 151–155.

    Article  PubMed  Google Scholar 

  10. Judo S, Kobayashi S, Nakajima Y, et al. Elevated serum levels of soluble Fas-APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 1998; 112: 166–171.

    Article  PubMed  Google Scholar 

  11. Konno R, Takano T, Sato S, Yajima A. Serum soluble Fas level as a prognostic factor in patents with gynecological malignancies. Clin Cancer Res 2000; 6: 3576–3580.

    PubMed  Google Scholar 

  12. Hefler L, Mayerhofer K, Nardi A, et al. Serum soluble Fas levels in ovarian cancer. Obstet Gynecol 2000; 96: 65–69.

    Article  PubMed  Google Scholar 

  13. Tanaka M, Itai T, Adachi M, et al. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31–36.

    Article  PubMed  Google Scholar 

  14. Tsutsumi S, Kuwano H, Shimura T, et al. Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 2000; 89: 2560–2564.

    Article  PubMed  Google Scholar 

  15. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996; 56: 3870–3874.

    PubMed  Google Scholar 

  16. Kato K, Ohshima K, Ishihara S, et al. Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. Br J Hematol 1998; 103: 1164–1166.

    Article  Google Scholar 

  17. Nagao M, Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo. Hepatology 1999; 30: 413–421.

    Article  PubMed  Google Scholar 

  18. Sheets EE, Yeh J. The role of apoptosis in gynaecological malignancies. Ann Med 1997; 29: 121–126.

    PubMed  Google Scholar 

  19. International Federation of Gynecologists and Obstetricians (FIGO). Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987; 156: 263–264.

    Google Scholar 

  20. Stellar H. Mechanism and genes of cellular suicide. Science 1995; 267: 1445–1449.

    Google Scholar 

  21. Lea GR, Riley SC, Antipatis C, et al. Cytokines and regulation of apoptosis in reproductive tissues: A review. Am J Reprod Immunol 1999; 42: 100–109.

    PubMed  Google Scholar 

  22. Nagata S. Fas-induced apoptosis. Int Med 1998; 37: 179–181.

    Google Scholar 

  23. Strand S, Hofmann W, Hug H, et al. Lymphocyte apoptosis induced by CD94 (APO-1/Fas) ligand-expressing tumor cells a mechanism of immune evasion. Nature Med 1996; 2: 1361–1366.

    Google Scholar 

  24. Mor G, Straszewski S, Kamsteeg M. Role of the Fas/Fas ligand system in female reproductive organs: Survival and apoptosis. Biochem Pharmacol 2002, 64: 1305–1315.

    Article  PubMed  Google Scholar 

  25. Song J, Rutherford T, Naftolin F, Brown S, Mor G. Hormonal regulation of apoptosis and the Fas and Fas ligand system in human endometrial cells. Mol Hum Reprod 2002; 8: 447–455.

    Article  PubMed  Google Scholar 

  26. Das H, Koizumi T, Sugimoto T, et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 2000; 82: 1682–1688.

    Article  PubMed  Google Scholar 

  27. Takagi A, Imai A, Horibe S, Ohno T, Tamaya T. Lack of evidence for expression of Fas ligand in Fas-bearing tumors. Oncol Rep 1998; 5: 377–380.

    PubMed  Google Scholar 

  28. Maher S, Toomey D, Condron C, et al. Activation-induced cell death: The controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002; 80: 131–137.

    Article  PubMed  Google Scholar 

  29. Owen-Schaub LB, Angelo LS, Radinsky R, et al. Soluble Fas/APO-1 in tumor cells: A potential regulator of apoptosis? Cancer Lett 1995; 94: 1–8.

    Article  PubMed  Google Scholar 

  30. Abrahams VM, Kamsteeg M, Mor G. The Fas/Fas ligand system and cancer: Immune privilege and apoptosis. Mol Biotechnol 2003; 25: 19–30.

    Article  PubMed  Google Scholar 

  31. Micheau O, Solary E, Hammann A, et al. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89: 783–789.

    Article  PubMed  Google Scholar 

  32. Abrahams VM, Straszewski SL, Kamsteeg M, et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003; 63: 5573–5581.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology and Serology, Medical University of Silesia, Raciborska 15, Katowice, 40-074, Poland

    Z. Kondera-Anasz, A. Mielczarek-Palacz & J. Sikora

Authors
  1. Z. Kondera-Anasz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Mielczarek-Palacz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Sikora
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Mielczarek-Palacz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kondera-Anasz, Z., Mielczarek-Palacz, A. & Sikora, J. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Apoptosis 10, 1143–1149 (2005). https://doi.org/10.1007/s10495-005-1018-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10495-005-1018-9

Keywords

Search

Navigation